Breaking News Instant updates and real-time market news.

KURA

Kura Oncology

$12.39

-1.99 (-13.84%)

12:48
10/22/18
10/22
12:48
10/22/18
12:48

H.C. Wainwright 'very encouraged' by Kura data, reiterates $31 price target

Kura Oncology this morning announced a positive outcome on its lead therapeutic candidate, tipifarnib, in Phase 2 clinical trial addressing the role of the drug in HRAS positive squamous cell carcinomas, H.C. Wainwright analyst Joseph Pantginis tells investors in a research note. The analyst believes the data show the validation of the therapeutic efficacy of tipifarnib and better clinical efficacy than current standards of care. "Although the market potential could seem minor, we are very encouraged tipifarnib represents a suitable and the first targeted therapy for HRAS high mutant HNSCC, and should open doors to initial tumor indications," writes Pantginis. He reiterates a Buy rating on Kura Oncology with a $31 price target.

  • 22

    Oct

  • 22

    Oct

KURA Kura Oncology
$12.39

-1.99 (-13.84%)

02/16/18
SBSH
02/16/18
NO CHANGE
Target $28
SBSH
Buy
Kura Oncology price target raised to $28 from $19 at Citi
Citi analyst Joel Beatty raised his price target for Kura Oncology to $28 citing increased confidence that Tipifarnib is a differentiated therapy for the treatment of HRAS mutant head and neck squamous cell cancer. The analyst sees a 55% probability of success. It is more probable than not that the five of eight, or 63% response rate observed thus far in head and neck squamous cell cancer is a "real efficacy signal," and the duration of response in this indication reinforces this view, Beatty tells investors in a research note. The analyst keeps a Buy rating on Kura Oncology.
02/16/18
OPCO
02/16/18
NO CHANGE
Target $30
OPCO
Outperform
Kura Oncology price target raised to $30 from $17.50 at Oppenheimer
Oppenheimer analyst Leah Rush Cann raised her price target for Kura Oncology to $30 citing the positive updated preliminary results from the company's Phase II study of tipifarnib in patients with HRAS mutant head and neck squamous cell carcinoma. The analyst increased her estimated revenue in 2020-2022 by 66.7% per year. She keeps an Outperform rating on Kura Oncology.
07/09/18
OPCO
07/09/18
NO CHANGE
Target $35
OPCO
Outperform
Kura Oncology price target raised to $35 from $27 at Oppenheimer
Oppenheimer analyst Leah Rush Cann raised her price target for Kura Oncology to $35 from $27, citing an increased average forward price-to-sales multiple of the biotechnology sector. The analyst reiterates an Outperform rating on the shares.
08/01/18
HCWC
08/01/18
INITIATION
Target $31
HCWC
Buy
Kura Oncology initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis started Kura Oncology with a Buy rating and $31 price target. The shares currently do not reflect the overall opportunity for tipifarnib, which is about to enter a pivotal program in head and neck squamous cell carcinoma patients as well as several other indications, which could lead to a broad label for the drug, Pantginis tells investors in a research note.

TODAY'S FREE FLY STORIES

MIK

Michaels

$12.78

0.99 (8.40%)

06:59
03/20/19
03/20
06:59
03/20/19
06:59
Downgrade
Michaels rating change  »

Michaels downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVRO

Nevro

$44.76

0.37 (0.83%)

06:59
03/20/19
03/20
06:59
03/20/19
06:59
Upgrade
Nevro rating change  »

Nevro upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 21

    Mar

UBSH

Union Bankshares

$34.56

-1.31 (-3.65%)

06:59
03/20/19
03/20
06:59
03/20/19
06:59
Initiation
Union Bankshares initiated  »

Union Bankshares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNAP

Snap

$10.63

-0.31 (-2.83%)

06:57
03/20/19
03/20
06:57
03/20/19
06:57
Periodicals
Snapchat admits age verification process is effectively useless, BI reports »

Snap's senior…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 04

    Apr

ZEAL

Zealand Pharma

$15.60

(0.00%)

06:57
03/20/19
03/20
06:57
03/20/19
06:57
Hot Stocks
Breaking Hot Stocks news story on Zealand Pharma »

Zealand Pharma AS (ADS)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SMAR

Smartsheet

$43.51

-0.16 (-0.37%)

06:57
03/20/19
03/20
06:57
03/20/19
06:57
Recommendations
Smartsheet analyst commentary  »

Smartsheet price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Apr

TXRH

Texas Roadhouse

$60.46

-0.39 (-0.64%)

06:56
03/20/19
03/20
06:56
03/20/19
06:56
Upgrade
Texas Roadhouse rating change  »

Texas Roadhouse upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAYRY

Bayer

$0.00

(0.00%)

, AZN

AstraZeneca

$42.87

0.29 (0.68%)

06:54
03/20/19
03/20
06:54
03/20/19
06:54
Recommendations
Bayer, AstraZeneca, Sanofi, Novartis, Merck analyst commentary  »

Bayer shares likely to…

BAYRY

Bayer

$0.00

(0.00%)

AZN

AstraZeneca

$42.87

0.29 (0.68%)

SNY

Sanofi

$45.18

0.27 (0.60%)

NVS

Novartis

$92.99

-0.205 (-0.22%)

MRK

Merck

$81.93

0.59 (0.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 22

    Mar

  • 25

    Mar

  • 11

    Apr

  • 28

    Apr

  • 30

    Apr

  • 18

    May

  • 17

    Jun

BA

Boeing

$373.87

1.77 (0.48%)

06:51
03/20/19
03/20
06:51
03/20/19
06:51
Periodicals
Off-duty pilot saved Lion Air 737 day before fatal crash, Bloomberg reports »

An off-duty pilot…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 28

    May

CTXS

Citrix

$101.31

-0.24 (-0.24%)

06:51
03/20/19
03/20
06:51
03/20/19
06:51
Conference/Events
Citrix to host CEMEX Day 2019 »

CEMEX Day 2019 to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 17

    Apr

IRM

Iron Mountain

$34.51

-0.29 (-0.83%)

06:51
03/20/19
03/20
06:51
03/20/19
06:51
Hot Stocks
Iron Mountain, MakeSpace announce partnership for storage services »

MakeSpace, an on-demand…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVDA

Nvidia

$175.77

6.86 (4.06%)

06:49
03/20/19
03/20
06:49
03/20/19
06:49
Recommendations
Nvidia analyst commentary  »

Nvidia price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKBA

Akebia

$8.12

-0.07 (-0.85%)

06:48
03/20/19
03/20
06:48
03/20/19
06:48
Initiation
Akebia initiated  »

Citi starts Akebia…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JMP

JMP Group

$3.79

-0.07 (-1.81%)

06:48
03/20/19
03/20
06:48
03/20/19
06:48
Hot Stocks
JMP Group sells majority interest in JMP Credit Advisors »

JMP Group has sold a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFE

Pfizer

$42.32

0.51 (1.22%)

06:47
03/20/19
03/20
06:47
03/20/19
06:47
Hot Stocks
Pfizer secures exclusive option to acquire Vivet Therapeutics »

Vivet Therapeutics and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 30

    Apr

  • 18

    May

FDX

FedEx

$181.50

-0.92 (-0.50%)

06:46
03/20/19
03/20
06:46
03/20/19
06:46
Recommendations
FedEx analyst commentary  »

FedEx remains 'story…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Apr

  • 02

    Apr

  • 25

    Jun

ENV

Envestnet

$66.69

0.29 (0.44%)

06:45
03/20/19
03/20
06:45
03/20/19
06:45
Downgrade
Envestnet rating change  »

Envestnet downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

06:45
03/20/19
03/20
06:45
03/20/19
06:45
General news
Breaking General news story  »

Week of 3/15 MBA Mortgage…

ZTS

Zoetis

$98.72

0.95 (0.97%)

06:43
03/20/19
03/20
06:43
03/20/19
06:43
Initiation
Zoetis initiated  »

Zoetis resumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TYL

Tyler Technologies

$204.57

0.855 (0.42%)

06:43
03/20/19
03/20
06:43
03/20/19
06:43
Conference/Events
Tyler Technologies management to meet with KeyBanc »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 21

    Mar

MO

Altria Group

$56.01

-1.295 (-2.26%)

06:42
03/20/19
03/20
06:42
03/20/19
06:42
Periodicals
FDA commissioner calls meeting with Altria, Juul 'difficult', CNBC reports »

Food and Drug…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 20

    Mar

  • 16

    May

TDC

Teradata

$48.33

0.58 (1.21%)

06:42
03/20/19
03/20
06:42
03/20/19
06:42
Downgrade
Teradata rating change  »

Citi downgrades Teradata…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

STL

Sterling Bancorp

$19.86

-0.39 (-1.93%)

06:40
03/20/19
03/20
06:40
03/20/19
06:40
Conference/Events
Sterling Bancorp management to meet with Piper Jaffray »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 21

    Mar

  • 22

    Mar

  • 18

    Jun

  • 19

    Jun

ELAN

Elanco

$33.00

1.36 (4.30%)

, ZTS

Zoetis

$98.72

0.95 (0.97%)

06:39
03/20/19
03/20
06:39
03/20/19
06:39
Initiation
Elanco, Zoetis initiated  »

Elanco resumed with a…

ELAN

Elanco

$33.00

1.36 (4.30%)

ZTS

Zoetis

$98.72

0.95 (0.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

ROK

Rockwell Automation

$178.71

-2.02 (-1.12%)

06:38
03/20/19
03/20
06:38
03/20/19
06:38
Downgrade
Rockwell Automation rating change  »

Rockwell Automation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.